HTG Molecular Diagnostics (HTGMQ) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 01, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1,169,987
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		28,421,711

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 5,774,356	$ 9,968,600
Short-term investments available-for-sale, at fair value	34,955,936
Accounts receivable	3,481,994	6,356,268
Inventory, net of allowance of $62,329 at June 30, 2018 and $62,142 at December 31, 2017	1,002,549	1,180,521
Prepaid expenses and other	845,170	443,068
Total current assets	46,060,005	17,948,457
Deferred offering costs		2,953
Deferred MidCap revolving loan costs	75,184
Property and equipment, net	2,888,995	3,304,890
Total assets	49,024,184	21,256,300
Current liabilities:
Accounts payable	1,306,917	2,438,798
Accrued liabilities	2,427,776	3,746,786
Contract liabilities - current	315,592	665,882
NuvoGen obligation - current	605,979	496,442
Growth Term Loan payable - net of discount and debt issuance costs		5,793,599
Other current liabilities	199,164	200,460
Total current liabilities	4,855,428	13,341,967
NuvoGen obligation - non-current, net of discount	6,970,277	7,520,913
Convertible note, related party - net of debt issuance costs	2,967,487	2,960,760
MidCap Term Loan payable - net of discount and debt issuance costs	6,626,886
Other non-current liabilities	389,490	492,197
Total liabilities	21,809,568	24,315,837
Commitments and Contingencies (Note 14)
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 200,000,000 shares authorized at June 30, 2018 and December 31, 2017, 28,414,524 shares issued and outstanding at June 30, 2018 and 13,929,763 shares issued and outstanding at December 31, 2017	28,414	13,929
Additional paid-in-capital	171,246,278	131,492,595
Accumulated other comprehensive loss	(11,339)
Accumulated deficit	(144,048,737)	(134,566,061)
Total stockholders’ equity (deficit)	27,214,616	(3,059,537)
Total liabilities and stockholders' equity (deficit)	$ 49,024,184	$ 21,256,300

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Inventory net allowance	$ 62,329	$ 62,142
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	28,414,524	13,929,763
Common stock, shares outstanding	28,414,524	13,929,763

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue:
Product and product-related services	$ 2,023,312	$ 1,458,345	$ 3,756,858	$ 2,829,514
Collaborative development services	2,887,454	302,411	5,312,560	302,411
Total revenue	4,910,766	1,760,756	9,069,418	3,131,925
Cost of revenue	1,450,682	1,236,904	2,587,745	2,532,206
Gross margin	3,460,084	523,852	6,481,673	599,719
Operating expenses:
Selling, general and administrative	4,764,751	4,413,437	10,422,583	8,651,904
Research and development	2,758,984	1,618,889	5,348,270	2,885,952
Total operating expenses	7,523,735	6,032,326	15,770,853	11,537,856
Operating loss	(4,063,651)	(5,508,474)	(9,289,180)	(10,938,137)
Other income (expense):
Interest expense	(233,306)	(350,058)	(415,823)	(748,478)
Interest income	197,773	17,630	330,936	29,719
Loss on extinguishment of Growth Term Loan			(105,064)
Total other income (expense)	(35,533)	(332,428)	(189,951)	(718,759)
Net loss before income taxes	(4,099,184)	(5,840,902)	(9,479,131)	(11,656,896)
Provision for income taxes	3,545		3,545	280
Net loss	$ (4,102,729)	$ (5,840,902)	$ (9,482,676)	$ (11,657,176)
Net loss per share, basic and diluted	$ (0.14)	$ (0.60)	$ (0.36)	$ (1.31)
Shares used in computing net loss per share, basic and diluted	28,375,379	9,769,322	26,549,895	8,875,177

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (4,102,729)	$ (5,840,902)	$ (9,482,676)	$ (11,657,176)
Other comprehensive income (loss), net of tax effect:
Unrealized gain (loss) on short-term investments	(188)	736	(11,339)	1,090
Comprehensive loss	$ (4,102,917)	$ (5,840,166)	$ (9,494,015)	$ (11,656,086)

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Deficit) - 6 months ended Jun. 30, 2018 - USD ($)	Total	ATM Offering	Underwritten Public Offering	Common Stock	Common StockATM Offering	Common StockUnderwritten Public Offering	Additional Paid-In Capital	Additional Paid-In CapitalATM Offering	Additional Paid-In CapitalUnderwritten Public Offering	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2017	$ (3,059,537)			$ 13,929			$ 131,492,595				$ (134,566,061)
Balance, shares at Dec. 31, 2017				13,929,763
Exercise of stock options	69,513			$ 34			69,479
Exercise of stock options, shares				33,651
Stock-based compensation expense	1,385,108						1,385,108
Vesting of restricted stock awards	270			$ 270
Vesting of restricted stock awards, shares				269,551
Net share settlement of restricted stock award	(133,513)			$ (35)			(133,478)
Net share settlement of restricted stock award, shares				(34,769)
Employee stock purchase plan	91,768			$ 40			91,728
Employee stock purchase plan, shares				39,976
Issuance of common stock		$ 556,706	$ 37,724,316		$ 261	$ 13,915		$ 556,445	$ 37,710,401
Issuance of common stock, shares					261,352	13,915,000
MidCap Term Loan warrant discount	74,000						74,000
Net loss	(9,482,676)										(9,482,676)
Other comprehensive loss	(11,339)									$ (11,339)
Balance at Jun. 30, 2018	$ 27,214,616			$ 28,414			$ 171,246,278			$ (11,339)	$ (144,048,737)
Balance, shares at Jun. 30, 2018				28,414,524

Condensed Statements of Change7

Condensed Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)	6 Months Ended
	Jun. 30, 2018USD ($)
Statement Of Stockholders Equity [Abstract]
Public offering issuance costs	$ 2,600,000
At the market offering, issuance costs	$ 17,000

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Operating activities
Net loss			$ (9,482,676)	$ (11,657,176)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	$ 422,140	$ 291,421	778,344	587,466
Accretion of discount on NuvoGen obligation			(6,006)	99,377
Provision for excess inventory	12,253	51,599	23,533	244,026
Amortization of Growth Term Loan discount and issuance costs			62,951	231,319
Loss on extinguishment of Growth Term Loan			105,064
Amortization of QNAH Convertible Note issuance costs			6,727
Amortization of MidCap Credit Facility discount and issuance costs			48,092
Stock-based compensation expense			1,385,378	814,583
Employee stock purchase plan expense			28,906	29,223
Accretion of incentive from landlord			(71,000)	(71,000)
Accrued interest on available-for-sale securities investments			(187,946)	5,991
Changes in operating assets and liabilities:
Accounts receivable			2,874,274	(173,427)
Inventory			191,836	(19,673)
Prepaid expenses and other			(402,102)	(35,103)
Deferred offering costs			2,953	49,630
Accounts payable			(656,645)	480,025
Accrued liabilities			(1,319,010)	(456,675)
Contract liabilities			(389,172)	278,310
Net cash used in operating activities			(7,006,499)	(9,593,104)
Investing activities
Purchase of property and equipment			(829,186)	(152,339)
Sales, redemptions and maturities of available-for-sale securities			3,300,000	4,300,000
Purchase of available-for-sale securities			(38,079,329)
Net cash (used in) provided by investing activities			(35,608,515)	4,147,661
Financing activities
Proceeds from MidCap Credit Facility			7,000,000
MidCap Credit Facility lender fees			(422,390)
Payments on Growth Term Loan			(1,684,626)	(3,126,629)
Payments for extinguishment of Growth Term Loan			(4,276,988)
Proceeds from public offering, net			37,932,290
Public offering costs			(207,974)
Proceeds from ATM Offering, net			556,706	14,705,770
Payments on NuvoGen obligation			(435,093)	(400,000)
Payments on capital leases			(40,017)	(24,796)
Proceeds from exercise of stock options			69,513	109,786
Taxes paid for net share settlement of restricted stock awards			(133,513)
Proceeds from shares purchased under the stock purchase plan			62,862	71,689
Net cash provided by financing activities			38,420,770	11,335,820
Increase (decrease) in cash and cash equivalents			(4,194,244)	5,890,377
Cash and cash equivalents at beginning of period			9,968,600	7,507,659	$ 7,507,659
Cash and cash equivalents at end of period	$ 5,774,356	$ 13,398,036	5,774,356	13,398,036	$ 9,968,600
Noncash investing and financing activities
Fixed asset purchases payable and accrued at period end			2,730	72,224
Deferred offering costs payable and accrued at period end				30,000
Carrying value of demonstration units transferred from property and equipment to inventory			49,245	26,807
Equipment purchased through capital lease			45,896
MidCap Term Loan fees and warrant discount			389,000
Retirement of treasury stock				75,000
Supplemental cash flow information
Cash paid for interest			202,573	417,782
Cash paid for taxes			$ 3,545	$ 280

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business HTG Molecular Diagnostics, Inc. (the “Company”) is a provider of instruments, reagents and services for molecular profiling applications. The Company derives revenue from sales of its HTG EdgeSeq automation system and integrated next-generation sequencing-based HTG EdgeSeq assays, from research services including sample processing and custom research use only (“RUO”) assay design and from collaborative development services. The Company operates in one segment and its customers are located primarily in the United States and Europe. For the three and six months ended June 30, 2018 approximately 74% and 76% of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 34% and 27% for the three and six months ended June 30, 2017. The increase in sales originated by customers located outside of the United States is primarily the result of collaborative development services revenue generated from the Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”), a wholly owned subsidiary of QIAGEN N.V. (see Note 16), which accounted for 80% and 77% of sales to customers located outside of the United States for the three and six months ended June 30, 2018, compared to 46% and 33% for the three and six months ended June 30, 2017.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying interim unaudited condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These interim unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2018. Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Revenue Recognition The Company adopted the Financial Accounting Standards Board (“FASB”) new revenue standard, Accounting Standards Codification 606, Revenue from Contracts with Customers (“ASC 606”), For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes. Contract Assets Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer, for which rights to payment are conditional upon something other than the passage of time. Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom RUO assay design and sample processing services and collaboration development services. When products or services outputs are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared to total expected costs as design or development procedures are completed and outputs are produced. Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq systems covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. This assurance-type warranty is not deemed to be a separate performance obligation under the Company’s contracts with customers for the sale of instruments, as its purpose is to ensure that the product complies with agreed-upon specifications following installation of the instrument. A provision for estimated warranty costs is recognized at the time of sale, through cost of revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed. Research and Development Expenses Research and development expenses represent costs incurred internally for research and development activities and costs incurred externally to fund research activities. The costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the accompanying interim unaudited condensed statements of operations. See Note 16 for further discussion of the development costs associated with collaborative development services agreements included in research and development expense as compared to cost of revenue in the accompanying interim unaudited condensed statements of operations. Debt Issuance Costs Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the accompanying interim unaudited condensed balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue revolving debt instruments are deferred as an asset in the accompanying interim unaudited condensed balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates. Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). As of June 30, 2018, the estimated aggregate fair value of the QNAH Convertible Note is approximately $3.4 million. The fair value estimate is based on the note’s discounted cash flows and estimated option value of the conversion terms. The estimated fair value of the QNAH Convertible Note represents a Level 3 measurement. The fair value of the MidCap Term Loan (see Note 8) is also estimated using Level 3 inputs and approximates fair value as the interest rate approximates the market rate for debt securities with similar terms and risk characteristics. The NuvoGen obligation is an obligation relating to an asset purchase transaction with a then-common stockholder of the Company. Although the obligation is considered a financial instrument, the Company is unable to reasonably determine its fair value as the remaining payments due under the obligation will be made at the greater of a minimum fixed quarterly payment or 6% of revenue, causing variability in the timing and amount of payments and the term of the obligation. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available-for-sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instrument, related consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top three customers accounted for 59%, 11% and 5% of the Company’s total revenue for the three months ended June 30, 2018, compared with 16%, 15% and 13% for the three months ended June 30, 2017. The top three customers accounted for 59%, 10% and 5% of the Company’s total revenue for the six months ended June 30, 2018, compared to 16%, 12% and 9% for the six months ended June 30, 2017. The top two customers accounted for approximately 59% and 15% of the Company’s accounts receivable as of June 30, 2018, compared with approximately 66% and 11% as of December 31, 2017. The largest of these amounts represents accounts receivable relating to statements of work entered into under the Company’s Governing Agreement with QML. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of processors, which in turn would materially affect the Company’s ability to generate revenue. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it were effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company adopted ASC 606 as of January 1, 2018 using the full retrospective approach. The adoption of ASC 606 did not have a material impact on 2017 revenue recognition or on opening equity, as the timing and measurement of revenue recognition is materially the same for the Company as under ASC 605. The Company has presented additional quantitative and qualitative disclosures regarding identified revenue streams and performance obligations beginning with the first quarter ended March 31, 2018 (see Note 9 and Note 16). The Company has also identified and implemented changes to its business processes and internal controls relating to implementation of the new standard. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting New Accounting Pronouncements The following are new FASB ASUs that have not been adopted by the Company as of June 30, 2018, grouped by their respective effective dates: January 1, 2019 In February 2016, the FASB issued ASU No. 2016-02, Leases, ‑ In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting January 1, 2020 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory

Inventory	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the dates indicated: June 30, December 31, 2018 2017 Raw materials $ 882,396 $ 984,328 Work in process 81,237 66,314 Finished goods 101,245 192,021 Total gross inventory 1,064,878 1,242,663 Less inventory allowance (62,329 ) (62,142 ) $ 1,002,549 $ 1,180,521 The reserve for shrinkage and excess inventory was $62,329 and $62,142 as of June 30, 2018 and December 31, 2017, respectively. For the three and six months ended June 30, 2018, the Company recorded adjustments in the inventory reserve of $(1,614) and $187, respectively, compared to net decreases of $66,250 and $62,427, respectively, for the three and six months ended June 30, 2017, to adjust for estimated shrinkage and obsolescence. For the three and six months ended June 30, 2018, the Company recorded adjustments to provision for excess inventory of $12,253 and $23,533, respectively. For the three and six months ended June 30, 2017, the Company recorded adjustments to provision for excess inventory of $51,599 and $244,026, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory have been included in cost of revenue in the accompanying interim unaudited

Fair Value Instruments

Fair Value Instruments	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Instruments	Note 4. Fair Value Instruments Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2018 and December 31, 2017, respectively: Balance at June 30, 2018 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 5,525,432 $ — $ — $ 5,525,432 Investments available-for-sale at fair value U.S. government obligations $ 11,989,585 $ — $ — $ 11,989,585 Corporate debt securities $ — $ 22,966,351 $ — $ 22,966,351 Total $ 17,515,017 $ 22,966,351 $ — $ 40,481,368 Balance at December 31, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 8,521,054 $ — $ — $ 8,521,054 Total $ 8,521,054 $ — $ — $ 8,521,054 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and six months ended June 30, 2018 or for the year ended December 31, 2017. Level 1 instruments include investments in money market funds, U.S. Treasuries and U.S. government agency obligations. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g., indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the six-month period ended June 30, 2018 or the year-ended December 31, 2017 and did not have any Level 3 financial assets or liabilities during either of these periods.

Available for Sale Securities

Available for Sale Securities	6 Months Ended
	Jun. 30, 2018
Investments Debt And Equity Securities [Abstract]
Available-for-Sale Securities	Note 5. Available-for-Sale Securities The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at June 30, 2018: June 30, 2018 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 11,997,649 $ — $ (8,064 ) $ 11,989,585 Corporate debt securities 22,969,626 — (3,275 ) 22,966,351 Total available-for-sale securities $ 34,967,275 $ — $ (11,339 ) $ 34,955,936 The Company had no available-for-sale securities at December 31, 2017. The net adjustment to unrealized holding gains (losses) on available-for-sale securities, net of tax in other comprehensive income totaled $(188) and $(11,339) for the three and six months ended June 30, 2018, and $736 and $1,090 Contractual maturities of debt investment securities at June 30, 2018 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 11,989,585 $ — $ 11,989,585 Corporate debt securities 22,966,351 — 22,966,351 Total available-for-sale securities $ 34,955,936 $ — $ 34,955,936 The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of June 30, 2018: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities $ 11,989,585 $ (8,064 ) $ — $ — $ 11,989,585 $ (8,064 ) Corporate debt securities 2,391,305 (3,275 ) — — 2,391,305 (3,275 ) Total available-for-sale securities with unrealized losses $ 14,380,890 $ (11,339 ) $ — $ — $ 14,380,890 $ (11,339 ) For debt securities, the Company determines whether it intends to sell or if it is more likely than not that it will be required to sell impaired securities. This determination considers current and forecasted liquidity requirements, regulatory and capital requirements and securities portfolio management. For all impaired debt securities for which there was no intent or expected requirement to sell, the evaluation considers all available evidence to assess whether it is likely the amortized cost value will be recovered. The Company conducts a regular assessment of its debt securities with unrealized losses to determine whether securities have other-than-temporary impairment considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral, market conditions and whether the Company intends to sell or it is more likely than not that the Company will be required to sell the debt securities. The Company did not have any other-than-temporary impairment in its available-for-sale securities at June 30, 2018 or December 31, 2017.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net, consists of the following as of the dates indicated: June 30, December 31, 2018 2017 Furniture & fixtures $ 686,349 $ 582,007 Leasehold improvements 1,895,216 1,863,698 Equipment used in manufacturing 2,147,331 1,963,558 Equipment used in research & development 1,456,954 1,328,556 Equipment used in the field 130,552 130,552 Software 373,683 373,683 Construction in progress 158,211 255,641 6,848,296 6,497,695 Less: accumulated depreciation and amortization (3,959,301 ) (3,192,805 ) $ 2,888,995 $ 3,304,890 Depreciation and leasehold improvement amortization expense was $422,140 and $778,344 for the three and six months ended June 30, 2018, respectively, and $291,421and $587,466 for the three and six months ended June 30, 2017, respectively.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2018
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following as of the dates indicated: June 30, December 31, 2018 2017 Accrued employee bonuses $ 1,365,489 $ 3,049,109 Payroll and employee benefit accruals 623,713 369,275 Accrued professional fees 112,320 101,150 Accrued interest 107,116 45,544 Other accrued liabilities 219,138 181,708 $ 2,427,776 $ 3,746,786

Debt Obligations

Debt Obligations	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations Growth Term Loan Total amortization expense for warrant, final fee and original issuance discounts in connection with the growth capital term loans under the Loan and Security Agreement dated August 22, 2014 between the Company and Oxford Finance, LLC and Silicon Valley Bank (the “Growth Term Loan”) was $0 and $59,969 for the three and six months ended June 30, 2018, respectively, and $103,741 and $220,731 for the three and six months ended June 30, 2017, respectively, and is included in interest expense in the accompanying interim unaudited condensed statements of operations. Deferred financing cost amortization expense relating to the Growth Term Loan was $0 and $2,982 for the three and six months ended June 30, 2018, respectively, and $4,995 and $10,588 for the three and six months ended June 30, 2017, respectively, and is included in interest expense in the accompanying interim unaudited interim unaudited Extinguishment of Growth Term Loan upon MidCap Credit Facility Closing In March 2018, the Company repaid all principal and interest amounts outstanding under the Growth Term Loan in an aggregate amount equal to approximately $4.3 million, including collateral agent legal fees and prepayment fees. The repayment was funded with net proceeds from the MidCap Credit Facility (see description of the MidCap Credit Facility below). As a result of the repayment, the Company recorded a loss on extinguishment of the Growth Term Loan of $0 for the three months ended June 30, 2018 and $105,064, including remaining unamortized discounts of $67,272 and prepayment and other Growth Term Loan lender fees in the accompanying condensed statements of operations for the six months ended June 30, 2018. MidCap Credit Facility On March 26, 2018 (the “MidCap Closing Date”), the Company entered into a Credit and Security Agreement (Term Loan) (the “MidCap Term Loan”) and a Credit and Security Agreement (Revolving Loan) (the “MidCap Revolving Loan” and together with the MidCap Term Loan, the “MidCap Credit Facility”) with MidCap Financial Trust, as agent. MidCap Financial Trust subsequently assigned its rights and obligations as agent to MidCap Funding IV Trust. The MidCap Term Loan provides a secured term loan facility in an aggregate principal amount of up to $20.0 million. The Company borrowed the first advance of $7.0 million (“MidCap Tranche 1”) on the MidCap Closing Date. Under the terms of the MidCap Term Loan, the second advance of $13.0 million (“MidCap Tranche 2”) will be available to the Company on or before September 30, 2019, subject to the Company’s satisfaction of certain conditions described in the MidCap Term Loan, including (a) the Company achieving the first commercial sale of an FDA-approved diagnostic assay utilizing next generation sequencing under its Governing Agreement with QML, and (b) delivery to MidCap of subordination documents in respect of the QNAH Convertible Note (or the satisfaction of alternative arrangements as provided in the MidCap Term Loan, as described below). MidCap Tranche 1 was used to repay in full all outstanding amounts and fees due under the Growth Term Loan. The proceeds remaining from MidCap Tranche 1 and, if borrowed, the proceeds from MidCap Tranche 2, are expected to be used for working capital and general corporate purposes. MidCap Tranche 1, and if borrowed MidCap Tranche 2, each bear interest at a floating rate equal to 7.25% per annum, plus the greater of (i) 1.25% or (ii) one-month LIBOR. Interest on each term loan advance is due and payable monthly in arrears and was calculated at a rate of 9.340% for interest accrued as of June 30, 2018. Principal on each term loan advance is payable in 36 equal monthly installments beginning April 1, 2020 until paid in full on March 1, 2023. Prepayments of the term loans under the MidCap Term Loan, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the MidCap Closing Date, 2.0% of principal prepaid if prepayment occurs after the first anniversary of the MidCap Closing Date but on or prior to the second anniversary of the MidCap Closing Date, and 1.0% of principal prepaid if prepayment occurs after the second anniversary of the MidCap Closing Date and prior to or on the third anniversary of the MidCap Closing Date. In connection with execution of the MidCap Term Loan, the Company paid MidCap a $100,000 origination fee. Upon termination of the MidCap Term Loan, the Company is required to pay an exit fee equal to 4.50% of the principal amount of all term loans advanced to the Company under the MidCap Term Loan. The MidCap Term Loan also requires that the Company deliver subordination documents with respect to the QNAH Convertible Note, or that the QNAH Convertible Note otherwise be converted or prepaid, on or before June 30, 2018, and requires the Company to deposit approximately $3.3 million into an escrow account by July 15, 2018 if neither of such events occurred by such date. See Note 17 for additional discussion relating to this requirement. The MidCap Revolving Loan provides a secured revolving credit facility in an aggregate principal amount of up to $2.0 million. The Company may request an increase in the total commitments under the MidCap Revolving Loan by up to an additional $8.0 million, subject to agent and lender approval and the satisfaction of certain conditions. Availability of the revolving credit facility under the MidCap Revolving Loan will be based upon a borrowing base formula and periodic borrowing base certifications valuing certain of the Company’s accounts receivable and inventory, as reduced by certain reserves, if any. Further, although the revolving credit facility was made available following establishment of required lockbox arrangements by the Company in June 2018, there were no amounts outstanding under the MidCap Revolving Loan as of June 30, 2018. The proceeds of any loans under the MidCap Revolving Loan may be used for working capital and general corporate purposes. Loans under the MidCap Revolving Loan accrue interest at a floating rate equal to 4.25% per annum, plus the greater of (i) 1.25% or (ii) one-month LIBOR. Accrued interest on the revolving loans will be paid monthly and revolving loans may be borrowed, repaid and re-borrowed until March 1, 2023, when all outstanding amounts must be repaid. Subject to certain exceptions, termination or permanent reductions of the revolving loan commitment under the MidCap Revolving Loan will be subject to termination fees in an amount equal to 3.0% of the commitment amount terminated or reduced if such termination or reduction occurs on or prior to the first anniversary of the MidCap Closing Date, 2.0% of the commitment amount terminated or reduced if such termination or reduction occurs after the first anniversary of the MidCap Closing Date but on or prior to the second anniversary of the MidCap Closing Date, and 1.0% of the commitment amount terminated or reduced if such termination or reduction occurs after the second anniversary of the MidCap Closing Date and prior to or on the third anniversary of the MidCap Closing Date. In connection with the MidCap Revolving Loan, the Company is required to pay customary fees, including an origination fee of 0.50% of the original commitment amount at closing (and an equivalent origination fee with respect to any increased commitments at the time of the applicable increase), a monthly unused line fee of 0.50% per annum based upon the average daily unused portion of the revolving credit facility and a monthly collateral management fee of 0.50% per annum based upon the average daily used portion of the revolving credit facility. The Company is also required to maintain a minimum drawn balance of not less 20% of availability under the revolving line. If the Company does not maintain such minimum drawn balance, it is required to pay monthly interest and fees as if an amount equal to 20% of availability had been drawn down under the revolving line. The Company’s obligations under the MidCap Credit Facility are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Facility. The MidCap Credit Facility contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. Commencing with the calendar quarter ending on the later of (a) June 30, 2019 and (b) the last day of the calendar quarter in which MidCap Tranche 2 is funded, the Company must also comply with a financial covenant relating to trailing twelve-month minimum Net Revenue requirements (as defined in the MidCap Credit Facility), tested on a quarterly basis. The MidCap Credit Facility also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, agent and the lenders may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 3.0%. The Company granted the lender ten-year warrants to purchase 18,123 shares of the Company’s common stock at $7.73 per share as a result of Tranche 1. Upon drawdown of Tranche 2, the Company will issue additional ten-year warrants to purchase shares of the Company’s common stock in an aggregate amount equal to 2.0% of the amount drawn, divided by the exercise price per share for that tranche (defined as 1.5 times the volume-weighted average closing price of the Company’s common stock for the ten business days immediately preceding the business day before the issue date). The fair value of the warrants on the date of issuance was approximately $74,000, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the MidCap Term Loan. The Company recognized approximately $729,269 of debt discount associated with the MidCap Term Loan, resulting from fees and debt issuance costs, in the accompanying interim unaudited condensed balance sheets as of June 30, 2018. Amortization of the debt discount associated with the MidCap Term Loan was approximately $41,155 and $43,856 for the three and six months ended June 30, 2018 and was included in interest expense in the accompanying interim unaudited condensed statements of operations. Costs incurred in connection with the issuance of the Midcap Revolving Loan of $75,184 are presented as MidCap revolving loan costs in the accompanying interim unaudited condensed balance sheets as of June 30, 2018. Amortization of deferred MidCap revolving loan costs was $4,013 and $4,236 for the three and six months ended June 30, 2018, respectively, and are included in interest expense in the accompanying interim unaudited condensed statements of operations. Other Debt Obligations to Related Parties Refer to Note 16 below for discussion of debt obligation to related parties.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2018
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 9. Revenue from Contracts with Customers Revenue from contracts with customers is recognized when, or as, the Company satisfies its performance obligations by delivering the promised goods or service deliverables to the customers. A good or service deliverable is transferred to a customer when, or as, the customer obtains control of that good or service deliverable. A performance obligation may be satisfied over time or at a point in time. Revenue from a performance obligation satisfied over time is recognized by measuring the Company’s progress in satisfying the performance obligation in a manner that depicts the transfer of the goods or services to the customer. Revenue from a performance obligation satisfied at a point in time is recognized at the point in time that the Company determines the customer obtains control over the promised good or service deliverable. The amount of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services ( i.e. Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and six months ended June 30, 2018 and 2017 as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Product revenue: Instruments $ 273,509 $ 148,479 $ 284,867 $ 171,058 Consumables 593,100 258,698 845,112 777,263 Total product revenue 866,609 407,177 1,129,979 948,321 Product-related services revenue: Custom RUO assay development 176,697 304,661 303,724 345,948 Sample processing 980,006 746,507 2,323,155 1,535,245 Total product-related services revenue 1,156,703 1,051,168 2,626,879 1,881,193 Total product and product-related services revenue $ 2,023,312 $ 1,458,345 $ 3,756,858 $ 2,829,514 Because the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Sale of Instruments and Consumables The delivery of each instrument and related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment. The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the accompanying interim unaudited condensed statements of operations as part of product and product-related services revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included in the accompanying interim unaudited condensed statements of operations as part of cost of revenue. For sales of consumables in the United States, standard delivery terms are FOB shipping point, unless otherwise specified in the customer contract, reflecting transfer of control to the customer upon shipment. The Company has elected the practical expedient to account for shipping and handling as activities to fulfill the promise to transfer the consumables. The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of its performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. The cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase in which case the instrument would be expensed as cost of revenue upon installation. Cost to maintain the instrument while title remains with the Company is charged to selling, general and administrative expense as incurred. Sample Processing The Company also provides sample processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment. Custom RUO Assay Design and Related Agreements The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared to total expected costs, as this is considered to be representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay development fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Bristol-Myers Squibb Company Agreement In May 2016, the Company entered into a Collaboration Agreement with Bristol-Myers Squibb Company (“BMS”) for the design of at least two custom RUO assays for BMS based on the Company’s HTG EdgeSeq technology. Following design of each assay, at BMS’s request, the Company may also perform sample processing services using such custom RUO assay(s) and/or supply the custom RUO assay(s) to BMS or its third-party subcontractors. Additional custom RUO assay design services related to immuno-oncology research may be undertaken pursuant to the agreement in accordance with a mutually acceptable work plan, which is incorporated by written amendment. BMS paid an initial non-refundable, non-creditable program set-up fee upon initiation of the agreement, and has agreed to pay an annual non-refundable, non-creditable project management fee in quarterly installments as well as a custom RUO assay design fee for each assay designed. In January 2018, the Company and BMS amended the terms of the parties’ Collaboration Agreement to increase the development fee payable by BMS to the Company for each of the two initial custom RUO assays contemplated by the agreement from a low six-figure range to a mid six-figure dollar amount, and to modify certain custom RUO assay design requirements. With the amendment of the agreement, the Company estimates that the first custom research assay design project initiated under this agreement will be completed before December 31, 2018. See contract liabilities note below for further discussion of the impact of this modification on the Collaboration Agreement. The Company has determined that the agreement does not meet the definition of a collaborative arrangement and that BMS meets the definition of a customer under ASC 606. Additionally, each SOW issued for an RUO custom assay design project contemplated by the agreement represents a single performance obligation to provide custom RUO assay design services. In addition, if BMS should opt to purchase completed custom RUO assay kits or sample processing services, these add-on services would not be combined with the custom RUO assay design performance obligations. Instead, these would be additional contracts with BMS accounted for using the Company’s policy for consumable product and sample processing revenue recognition under ASC 606 at the time such request is made. The initial set-up fee is a fixed fee and is included in the transaction price. The RUO custom assay design fee relating to each assay design project contemplated under the agreement represents variable consideration because the assay design fees are contingent upon completion of each phase of the design project and the decision of BMS to proceed to the next phase. The quarterly project management fees represent variable consideration because they are payable by BMS through the completion of the second of the two custom assay design projects or termination of the agreement. The Company uses the most likely amount method to measure the variable consideration for its RUO custom assay design fees, which are constrained and excluded from the transaction price until BMS is contractually obligated to pay the fees upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The initial set-up fee is included in the transaction price and is being recognized as revenue using an output method that measures progress based on the specific output provided to BMS, such as an internal document generated or conclusion reached. The agreement will expire on May 11, 2019 or, if a project is then ongoing, the date of delivery of the final report for such project. Either party may terminate the agreement upon the other party’s material breach or default in the performance of a material obligation under the agreement or if certain warranties or representations are untrue in any material respect (each a “BCA Default”) and such BCA Default remains uncured for 60 90 For the three and six months ended June 30, 2018, $70,919 and $132,224, respectively, was recognized under the agreement as product and product-related services revenue in the accompanying interim unaudited condensed statements of operations, compared to $31,250 and $62,500 for the three and six months ended June 30, 2017, respectively. Contract liabilities relating to this agreement of $90,382 and $160,106 were included in the accompanying interim unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017, respectively. As of June 30, 2018, the aggregate amount of the transaction price allocated to the partially unsatisfied performance obligation was $50,000. The Company expects to recognize the revenue for this amount between July 2018 and December 2019 using the same output method that the Company uses for its custom RUO assay design performance obligations with BMS. Collaborative Development Services Revenue Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Collaborative development services $ 2,887,454 $ 302,411 $ 5,312,560 $ 302,411 See Note 16 for discussion of collaborative development services contracts with related parties. There was no collaborative development services revenue generated from the Company’s companion diagnostic development services agreements with non-related party customers for the three and six months ended June 30, 2018. This includes the Company’s Master CDx Agreement with Merck KGaA, Darmstadt, Germany, for which there have been no significant modifications or financial events relating to the agreement since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2018. The Company earned the first milestone-based payment under the Master CDx Agreement in the second quarter of 2017, resulting in recognition of $25,000 of collaborative development services revenue for the three and six months ended June 30, 2017. Contract Liabilities The Company receives up-front payments from customers for custom RUO assay design services, and occasionally for sample processing services. Payments for instrument extended warranty contracts are made in advance as are payments for certain agreed-upon capital purchases required for collaborative development service projects. The Company recognizes such up-front payments as a contract liability. The contract liability is subsequently reduced at the point in time that the data file is delivered for sample processing services or as the Company satisfies its performance obligations over time for RUO assay design, collaborative development and extended warranty services. Contract liabilities of $448,717 and $837,885 were included in contract liabilities – current and other non-current liabilities in the accompanying unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017, respectively. Changes in the Company’s contract liability were as follows as of the date indicated: Product Revenue Custom RUO Assay Design Sample Processing Collaborative Development Services Total Contract Liability Balance at January 1, 2018 $ 39,426 $ 197,606 $ 354,911 $ 245,942 $ 837,885 Deferral of revenue 90,353 231,500 72,540 70,918 465,311 Recognition of deferred revenue (91,797 ) (301,224 ) (262,723 ) (198,735 ) (854,479 ) Balance at June 30, 2018 $ 37,982 $ 127,882 $ 164,728 $ 118,125 $ 448,717 Included in recognition of deferred revenue for the three and six months ended June 30, 2018 was a cumulative catch up adjustment of $0 and $30,055, respectively, to custom RUO assay design revenue relating to the January 2018 modification of the Company’s Collaboration Agreement with BMS for custom RUO assay design discussed above.

Other Agreements

Other Agreements	6 Months Ended
	Jun. 30, 2018
Other Agreements [Abstract]
Other Agreements	Note 10. Other Agreements NuvoGen Obligation Pursuant to the Company’s asset purchase agreement with NuvoGen Research, LLC (“NuvoGen”), as amended, the Company is obligated to pay NuvoGen the greater of $400,000 or 6% of annual revenue until the obligation is paid in full. Although an amendment to the agreement allowed for deferral of any revenue-based payments through December 31, 2017, no revenue-based payments were deferred. In addition to fixed quarterly payments of $100,000, revenue-based payments of $194,646 and $85,574 were payable as of June 30, 2018 and December 31, 2017, respectively. There have been no significant modifications to the terms and conditions of the Company’s NuvoGen obligation since the disclosures made in the Company’s Annual Report on Form 10-K, filed with the SEC on March 23, 2018. The minimum remaining payments due to NuvoGen at June 30, 2018, including $194,646 of additional revenue-based payments payable as of June 30, 2018, are as follows for each fiscal year, although actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue exceeds $400,000: 2018 $ 394,646 2019 400,000 2020 400,000 2021 400,000 2022 400,000 2023 and beyond 5,469,004 Total NuvoGen obligation payments 7,463,650 Plus interest accretion 112,606 Total NuvoGen obligation, net $ 7,576,256 Illumina, Inc. Agreement In June 2017, the Company entered into an Amended and Restated Development and Component Supply Agreement with Illumina, Inc. (“Illumina”), effective May 31, 2017 (“Restated Agreement”), which amended and restated the parties’ IVD Test Development and Component Supply Agreement entered into in October 2014 (“Original Agreement”). The Restated Agreement provides for the development and worldwide commercialization by the Company of nuclease-protection-based RNA or DNA profiling tests (“IVD test kits”) for use with Illumina’s MiSeqDx sequencer in the field of diagnostic oncology testing in humans (“Field”). The Company submitted a development plan for an IVD test kit to Illumina, resulting in a required payment to Illumina of $50,000 for the three and six months ended June 30, 2017. There have been no financial events relating to the Restated Agreement for the three and six months ended June 30, 2018. Other Development Agreements There have been no significant modifications or financial events relating to the development agreements entered into by the Company in prior periods with Invetech PTY Ltd. since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2018.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Net Loss per Share	Note 11. Net Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per The following table provides the numerator and denominator used in computing basic and diluted net loss per share for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator: Net loss $ (4,102,729 ) $ (5,840,902 ) $ (9,482,676 ) $ (11,657,176 ) Denominator: Weighted-average shares outstanding-basic and diluted 28,375,379 9,769,322 26,549,895 8,875,177 Net loss per share, basic and diluted $ (0.14 ) $ (0.60 ) $ (0.36 ) $ (1.31 ) The following outstanding securities were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2018 2017 Options to purchase common stock 1,693,575 1,436,978 Common stock warrants 237,846 219,723 Restricted stock units 26,666 208,999 QNAH convertible note 766,381 —

Warrants

Warrants	6 Months Ended
	Jun. 30, 2018
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 12. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock which have since been converted to common stock warrants. There have been no significant modifications or financial events relating to the warrants that were issued prior to December 31, 2017 since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2018. In March 2018, in connection with the Company’s entry into the MidCap Credit Facility (see Note 8), the Company issued warrants to purchase an aggregate of 18,123 shares of the Company’s common stock, at an exercise price equal to $7.73 per share as a result of the funding of MidCap Tranche 1. The warrants are immediately exercisable and expire on the earlier to occur of the tenth anniversary of the respective issue date or, in certain circumstances, the closing of a merger, sale or other consolidation transaction in which the consideration is cash, stock of a publicly traded acquirer, or a combination thereof. The following table shows the common stock warrants outstanding as of June 30, 2018: Shares of Common Exercise Price/Share Expiration Date 28,713 23.51 2024 144,772 14.00 2022 931 6.45 2019 45,307 2.76 2026 18,123 7.73 2028

Stockholders Deficit

Stockholders Deficit	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Stockholders' Deficit	Note 13. Stockholders’ Deficit Public Offerings ATM Offering In April 2017, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which the Company had the right to offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “ATM Offering”). In April 2017, the Company also filed a prospectus supplement (File No. 333-216977) with the SEC relating to the offer and sale of up to $20.0 million of common stock in the ATM Offering. In June 2017, the Company filed a first amendment to the prospectus supplement with the SEC to increase the amount of common stock that could be offered and sold in the ATM Offering under the Sales Agreement to $40.0 million in the aggregate, inclusive of the common stock previously sold in the ATM Offering prior to the date of the first amendment. In January 2018, the Company filed a second amendment to the prospectus supplement with the SEC to decrease the amount of common stock that could be offered and sold in the ATM Offering under the Sales Agreement to $23.0 million in the aggregate, inclusive of the common stock sold in the ATM Offering prior to the date of the second amendment. In February 2018, the Company and Cantor mutually agreed to terminate the Sales Agreement. Prior to termination of the Sales Agreement, the Company sold 5,733,314 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $21.1 million, including 0.3 million shares of common stock sold for gross proceeds of $0.6 million during the first quarter ended March 31, 2018. After $0.6 million of sales commissions and $0.2 million of other offering expenses paid by the Company in connection with the ATM Offering, the Company’s aggregate net proceeds from the ATM Offering were approximately $20.2 million. Sales commissions and offering expenses have been recorded as a reduction of proceeds received in arriving at the amount recorded in additional paid-in capital in the accompanying interim unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017. Underwritten Public Offering In January 2018, the Company completed an underwritten public offering of 13,915,000 shares of its common stock at a price of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The Company sold its common stock through an underwriting agreement with Leerink Partners LLC and Cantor as representatives of the underwriters for the offering. The aggregate net proceeds to the Company from the offering were approximately $37.7 million, after deducting the underwriting discounts and commissions and offering expenses. Stock-based Compensation A summary of the Company’s stock option activity for the six months ended June 30, 2018 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2017 1,517,771 $ 2.97 7.5 $ 67,242 Granted 272,500 3.38 Exercised (33,651 ) 2.07 $ 51,816 Forfeited (23,190 ) 3.60 Expired/Cancelled (39,855 ) 6.83 Balance at June 30, 2018 1,693,575 $ 2.95 7.4 $ 1,262,339 Exercisable at June 30, 2018 1,163,017 $ 2.89 6.6 $ 1,061,522 As of June 30, 2018, there was total unrecognized compensation expense of $937,490 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 2.98 years. In June 2018, in connection with the retirement of two employees, the vesting of stock options covering 46,613 shares of common stock was accelerated, and the post-termination exercise period for the employees’ options were extended to a one year period from the termination date. As a result of this modification, the Company recorded incremental stock-based compensation expense of approximately $79,400 for the three and six months ended June 30, 2018. A summary of restricted stock unit (“RSU”) activity for the six months ended June 30, 2018 is as follows: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2017 26,666 $ 2.78 Granted 269,551 3.82 Vested (269,551 ) 3.76 Balance at June 30, 2018 26,666 $ 3.34 Unrecognized compensation expense related to the remaining unvested RSUs was $70,313 at June 30, 2018, which the Company expects to recognize over a weighted-average remaining service period of 2.56 years. Stock-based compensation expense recorded in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018 and 2017 was as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Selling, general and administrative $ 173,666 $ 294,591 $ 1,275,658 $ 574,174 Research and development 49,189 93,103 80,098 181,464 Cost of revenue 19,065 30,243 29,622 58,945 $ 241,920 $ 417,937 $ 1,385,378 $ 814,583 Stock-based compensation expense for the three and six months ended June 30, 2018 included $1.0 million of selling, general and administrative compensation expense relating to the issuance of 259,551 shares under restricted stock units (“RSUs”) granted to the Company’s executive officers in January 2018 at a grant date fair value of $3.84 per share. The RSUs vested in full on January 29, 2018.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Compensation Agreements In September 2017, the Company entered into an arrangement with certain of its non-executive officer employees to provide for retention bonus payments to those eligible employees providing continuing service to the Company through July 31, 2018 and December 31, 2018, with one half of the retention bonus commitment payable at each of these dates. Compensation expense of $244,588 and $472,813 has been included in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018, respectively. Retention bonus accrual is included in accrued liabilities in the accompanying interim unaudited condensed balance sheets as of June 30, 2018. The remaining retention bonuses will be accrued on a straight-line basis through December 31, 2018. No forfeiture rate has been estimated. Forfeitures will be recognized as they occur. Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Leases The Company leases office and laboratory space in Tucson, Arizona under two non-cancelable operating leases. There have been no changes to the Company’s office and laboratory space leases since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2018. The Company’s remaining minimum real estate lease payments before common area maintenance charges for each fiscal year as of June 30, 2018 are as follows: 2018 $ 256,166 2019 514,977 2020 517,457 2021 43,139 $ 1,331,739 As of June 30, 2018, the Company also has remaining capital lease commitments consisting of approximately $88,700 for computer equipment varying in length from 36 to 48 months that has not been included in the minimum lease payments schedule above. Product Warranty The following is a summary of the Company’s general product warranty reserve for the periods indicated: Six Months Ended June 30, 2018 2017 Beginning balance $ 37,156 $ 50,426 Cost of warranty claims (2,358 ) (4,296 ) Increase (decrease) in warranty reserve 24,857 (14,817 ) Ending balance $ 59,655 $ 31,313 Warranty reserve is included in accrued liabilities in the accompanying interim unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017. Expense relating to the recording of this reserve is recorded in cost of revenue within the accompanying interim unaudited condensed statements of operations.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as it is not more likely than not that these will be realized. As a result, the Company has not recorded any federal or state income tax benefit in the accompanying interim unaudited The Company periodically reviews its filing positions for all open tax years in all U.S. federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained in a court of last resort. The term “more likely than not” means a likelihood of more than 50 percent. Otherwise, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the more likely than not criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. The Company has not identified any uncertain tax positions at June 30, 2018 or December 31, 2017. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at June 30, 2018 and December 31, 2017, respectively, and has not recognized interest or penalties of significance during the three months ended June 30, 2018 and 2017, respectively, since there are no material unrecognized tax benefits. The Company has not made or had payments due for income taxes for the periods ended June 30, 2018 or December 31, 2017, other than state minimum taxes. Management believes no material change to the amount of unrecognized tax benefits will occur within the next 12 months. The Company has established a valuation allowance against the entire net deferred tax asset. A preliminary analysis of past and subsequent equity offerings by the Company, and other transactions that have an impact on the Company’s ownership structure, concluded that the Company may have experienced one or more ownership changes under Sections 382 and 383 of the Internal Revenue Code or IRC. Provisions of the IRC place special limitations on the usage of net operating losses and credits following an ownership change. Such limitations may limit or eliminate the potential future tax benefit to be realized by the Company from its accumulated net operating losses and research and development credits. On December 22, 2017, federal tax legislation commonly referred to as the Tax Cuts and Jobs Act (“Tax Act”) was signed into law. The Tax Act, among other changes, reduced the U.S. federal corporate tax rate from 35% to 21%, effective January 1, 2018. Consequently, for the year ended December 31, 2017, the Company recorded a decrease related to deferred tax assets of $16,232,211, exclusive of the corresponding change in the valuation allowance. Due to the full valuation allowance on the deferred tax assets, there was no net adjustment to the deferred tax expense or benefit due to the reduction of the corporate tax rate. Other changes effective January 1, 2018 include, but are not limited to, creating a new limitation on deductible interest expense, eliminating the corporate alternative minimum tax, modifying the rules related to uses and limitations of net operating loss carryforwards generated in tax years ending after December 31, 2017, limiting the deductibility of certain executive compensation, and changing the rules pertaining to the taxation of profits earned abroad. The Company expects to be subject to the new limitation on deductible interest expense in 2018; however, the disallowed interest may be carried forward indefinitely. The Company’s net operating losses generated in 2018 and thereafter, if any, will be subject to a new indefinite carryforward period; however, utilization of these net operating losses will be limited to 80% of taxable income in the year utilized. Net operating loss carryforwards existing as of December 31, 2017 will not be subject to this new limitation; however, those carryforwards will remain subject to the 20-year expiration period.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 16. Related Party Transactions Master Assay Development, Commercialization and Manufacturing Agreement In November 2016, the Company entered into the Governing Agreement, which creates the framework for QML and the Company to combine their technological and commercial strengths to offer biopharmaceutical companies a complete NGS-based solution for the development, manufacture and commercialization of companion diagnostic assays. Under the Governing Agreement, the parties jointly seek companion diagnostic programs with biopharmaceutical companies, QML enters into sponsor project agreements with interested biopharmaceutical companies for specified projects, and QML and the Company enter into statements of work (each, an “SOW”), which set forth the rights and obligations of QML and the Company with respect to each project. There have been no significant modifications or financial events relating to the Governing Agreement since the disclosures made by the Company in its Annual Report on Form 10‑K, filed with the SEC on March 23, 2018, other than with regard to the initiation of new SOWs under the Governing Agreement as discussed below. The Company has determined that SOW One, SOW Two and SOW Three (each defined below) are collaborative arrangements and that QML meets the definition of a customer under ASC 606. Additionally, each SOW is a separate contract with a single performance obligation to provide development services. Under each SOW, QML pays the Company a monthly fee for development work performed by the Company and its subcontractors (collectively, the “Monthly Fee”). The Monthly Fee is based on the employee and materials costs incurred during the month, which is subject to significant variability from period to period and unknown until the costs are incurred. Therefore, the Monthly Fee, which is based on use of hours and costs as a measure of progress, is included in the transaction price and recognized as revenue over time when the costs are incurred and the Monthly Fee is billed to QML. It is at this time that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company and QML also will share any net profits resulting from performance of the development work as determined pursuant to the Governing Agreement. Such profit sharing payment(s) is deemed to be variable consideration using the expected value method and is included in the transaction price upon completion of the respective SOW deliverables, acceptance of corresponding deliverables, and the mutual agreement by QML and the Company on the calculation of net profit, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Because each SOW has an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations for each SOW. Statement of Work No. One In June 2017, the Company and QML entered into the first statement of work under the Governing Agreement, which has been twice amended in December 2017 and March 2018 (collectively, “SOW One”). SOW One addressed the activities of the Company and QML in support of the development and potential commercialization of a next generation sequencing-based companion diagnostic assay that was the subject of a sponsor project agreement between QML and a biopharmaceutical company (“Pharma One”). In May 2018, SOW One was terminated by QML as a result of Pharma One’s termination of the development project. The Company has discontinued development activities related to the project following wind down activities completed in the second quarter of 2018. Revenue of $1,078,418 and $2,397,136, including SOW One Monthly Fees and $0 and $99,394 of SOW One profit sharing payments has been included in collaborative development services revenue in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018, respectively, compared to $277,400, including only SOW One Monthly Fees, for both the three and six months ended June 30, 2017. Accounts receivable relating to SOW One of $429,019 and $2,429,152 remained in the accompanying interim unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017, respectively. Costs relating to development activities conducted by the Company pursuant to SOW One of $669,994 and $1,716,115 have been included in research and development expense in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018, respectively, compared to $222,200 for both the three and six months ended June 30, 2017. Statement of Work No. Two In October 2017, the Company and QML entered into the second statement of work under the Governing Agreement (“SOW Two”). SOW Two was made effective as of June 2, 2017 (“Onset Date”). SOW Two addresses development activities conducted by the Company and QML since the Onset Date and those expected to be further conducted by parties in connection with a sponsor project agreement, dated June 2, 2017, between QML and BMS (the “BMS/QML SPA”). See Note 17 for further discussion of SOW Two. Revenue of $869,827 and $1,480,818, including SOW Two Monthly Fees and $0 and $386,369 of SOW Two profit sharing payments, have been included in collaborative development services revenue in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018, respectively. Accounts receivable relating to SOW Two of $729,448 and $1,796,157 remained in the accompanying interim unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017, respectively. Costs relating to development activities conducted by the Company pursuant to SOW Two of $420,876 and $764,142 have been included in research and development expense in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018, respectively. No costs or revenue relating to SOW Two were included in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2017 as SOW Two was not established until October 2017. Statement of Work No. Three In January 2018, the Company and QML entered into a third statement of work (“SOW Three”) under the Governing Agreement. SOW Three relates to development activities for a next generation sequencing-based clinical-trial assay (“SOW Three Project”) in connection with a sponsor project agreement between QML and a pharmaceutical company (“Pharma Three”). If successfully completed, the SOW Three Project is expected to lead to subsequent assay development activities and the potential commercialization of a companion diagnostic assay for a corresponding Pharma Three drug. Under the terms of SOW Three, the Company has agreed to assign its rights in certain SOW Three Project-related intellectual property (“Project IP”) predominantly related to Pharma Three’s drug candidate(s) to QML for ultimate assignment to Pharma Three in accordance with the sponsor project agreement between QML and Pharma Three. Improvements to the background intellectual property of the Company, QML and Pharma Three generally will be owned solely by the respective party. Otherwise, Project IP will be jointly owned among the Company, QML and Pharma Three. SOW Three expires upon completion of the SOW Three Project and receipt by the Company of all amounts due for such work . QML will pay the Company for the initial phase development services performed for SOW Three. In addition, the Company and QML will share in any net profits (as determined under the Governing Agreement) generated during the initial phase work on an approximately quarterly basis throughout the term of SOW Three. Revenue of $939,209 and $1,434,606, including SOW Three Monthly Fees and $0 and $146,491, respectively, relating to SOW Three profit sharing payments, have been included in collaborative development services revenue in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018, respectively. Accounts receivable relating to SOW Three of $879,526 and $0 remained in the accompanying interim unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017, respectively. Costs relating to development activities conducted by the Company pursuant to SOW Three of $627,709 and $854,564 have been included in research and development expense in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018, respectively. No costs or revenue relating to SOW Three were included in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2017 as SOW Three was not established until January 2018. QNAH Convertible Note Agreement In October 2017, the Company issued a subordinated convertible promissory note to QNAH in the principal amount of $3.0 million against receipt of cash proceeds equal to such principal amount. There have been no significant modifications or financial events relating to QNAH Convertible Note since disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2018 other than the initiation of an escrow account relating to this note in July 2018 (see Note 17). The Company has recognized $32,513 and $39,240 of unamortized deferred financing costs incurred in connection with the issuance of the note under the QNAH Convertible Note in the accompanying interim unaudited condensed balance sheets as of June 30, 2018 and December 31, 2017, respectively. Amortization of the QNAH Convertible Note deferred financing costs was $3,364 and $6,727 for the three and six months ended June 30, 2018, respectively. Interest accrued on the QNAH Convertible Note during the three and six months ended June 30, 2018 was $22,438 and $44,630, respectively. Both amounts are included in interest expense in the accompanying interim unaudited statements of operations for the three and six months ended June 30, 2018. There was no interest accrual or deferred financing cost amortization relating to the QNAH Convertible Note for the three and six months ended June 30, 2017.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events MidCap Term Loan Escrow The MidCap Term Loan (see Note 8) required that the Company deliver subordination documents with respect to the QNAH Convertible Note, or that the QNAH Convertible Note otherwise be converted or prepaid, on or before June 30, 2018, and required the Company to deposit approximately $3.3 million into an escrow account by July 15, 2018 if neither of such events occurred by such date. As neither of these events occurred prior to June 30, 2018, the Company deposited approximately $3.3 million into an escrow account on July 11, 2018. Such escrowed funds will be released to the Company upon subsequent delivery of the requisite subordination documents or conversion of the QNAH Convertible Note. If neither delivery of the subordination documents or conversion of the QNAH Convertible Note occurs, such funds will be applied by the escrow agent to repay in full the QNAH Convertible Note at maturity (or in connection with a prepayment at the direction of the Company), subject to (i) the Company having drawn MidCap Tranche 2, (ii) the Company having unrestricted cash and cash equivalents held in a deposit or securities account subject to a control agreement in favor of the Agent in a minimum amount of $20.0 million and (iii) there being no default under the MidCap Credit Facility. Statement of Work No. Two Amendment On August 8, 2018, the Company and QML entered into an amendment to SOW Two (see Note 16), effective as of July 2, 2018, which relates to a project for which HTG and QML are performing collaborative development services for what is expected to be a multi-stage project leading to the potential development and commercialization of an NGS-based companion diagnostic assay in support of one or more of BMS’ therapeutic development and commercialization programs. Initial-phase investigational use only (“IUO”) development activities under SOW Two have been completed and the amendment of SOW Two relates to the next phase, which includes the use of the IUO assay developed in the initial-phase in a retrospective clinical trial. Successful completion of the next phase activities could lead to the use of the assay in subsequent clinical trials and potential companion diagnostic development. The next phase activities expected to be performed by the Company and QML under the first amendment to SOW Two are expected to be completed within the third quarter of 2018. QML will pay the Company approximately $0.5 million for work to be performed under this amendment, including project management, clinical affairs support and oversight of clinical trial by the Company and its subcontractors. In addition, the Company and QML will share in any net profits (as determined under the Governing Agreement) generated by this next phase work.

Basis of Presentation and Sum26

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying interim unaudited condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These interim unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2018.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.
Revenue Recognition	Revenue Recognition The Company adopted the Financial Accounting Standards Board (“FASB”) new revenue standard, Accounting Standards Codification 606, Revenue from Contracts with Customers (“ASC 606”), For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes.
Contract Assets	Contract Assets Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer, for which rights to payment are conditional upon something other than the passage of time.
Contract Liabilities	Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom RUO assay design and sample processing services and collaboration development services. When products or services outputs are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared to total expected costs as design or development procedures are completed and outputs are produced.
Product Warranty	Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq systems covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. This assurance-type warranty is not deemed to be a separate performance obligation under the Company’s contracts with customers for the sale of instruments, as its purpose is to ensure that the product complies with agreed-upon specifications following installation of the instrument. A provision for estimated warranty costs is recognized at the time of sale, through cost of revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed.
Research and Development Expenses	Research and Development Expenses Research and development expenses represent costs incurred internally for research and development activities and costs incurred externally to fund research activities. The costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the accompanying interim unaudited condensed statements of operations. See Note 16 for further discussion of the development costs associated with collaborative development services agreements included in research and development expense as compared to cost of revenue in the accompanying interim unaudited condensed statements of operations.
Debt Issuance Costs	Debt Issuance Costs Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the accompanying interim unaudited condensed balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue revolving debt instruments are deferred as an asset in the accompanying interim unaudited condensed balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). As of June 30, 2018, the estimated aggregate fair value of the QNAH Convertible Note is approximately $3.4 million. The fair value estimate is based on the note’s discounted cash flows and estimated option value of the conversion terms. The estimated fair value of the QNAH Convertible Note represents a Level 3 measurement. The fair value of the MidCap Term Loan (see Note 8) is also estimated using Level 3 inputs and approximates fair value as the interest rate approximates the market rate for debt securities with similar terms and risk characteristics. The NuvoGen obligation is an obligation relating to an asset purchase transaction with a then-common stockholder of the Company. Although the obligation is considered a financial instrument, the Company is unable to reasonably determine its fair value as the remaining payments due under the obligation will be made at the greater of a minimum fixed quarterly payment or 6% of revenue, causing variability in the timing and amount of payments and the term of the obligation.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents, available-for-sale debt securities and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instrument, related consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top three customers accounted for 59%, 11% and 5% of the Company’s total revenue for the three months ended June 30, 2018, compared with 16%, 15% and 13% for the three months ended June 30, 2017. The top three customers accounted for 59%, 10% and 5% of the Company’s total revenue for the six months ended June 30, 2018, compared to 16%, 12% and 9% for the six months ended June 30, 2017. The top two customers accounted for approximately 59% and 15% of the Company’s accounts receivable as of June 30, 2018, compared with approximately 66% and 11% as of December 31, 2017. The largest of these amounts represents accounts receivable relating to statements of work entered into under the Company’s Governing Agreement with QML. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of processors, which in turn would materially affect the Company’s ability to generate revenue.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it were effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company adopted ASC 606 as of January 1, 2018 using the full retrospective approach. The adoption of ASC 606 did not have a material impact on 2017 revenue recognition or on opening equity, as the timing and measurement of revenue recognition is materially the same for the Company as under ASC 605. The Company has presented additional quantitative and qualitative disclosures regarding identified revenue streams and performance obligations beginning with the first quarter ended March 31, 2018 (see Note 9 and Note 16). The Company has also identified and implemented changes to its business processes and internal controls relating to implementation of the new standard. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting New Accounting Pronouncements The following are new FASB ASUs that have not been adopted by the Company as of June 30, 2018, grouped by their respective effective dates: January 1, 2019 In February 2016, the FASB issued ASU No. 2016-02, Leases, ‑ In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting January 1, 2020 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the dates indicated: June 30, December 31, 2018 2017 Raw materials $ 882,396 $ 984,328 Work in process 81,237 66,314 Finished goods 101,245 192,021 Total gross inventory 1,064,878 1,242,663 Less inventory allowance (62,329 ) (62,142 ) $ 1,002,549 $ 1,180,521

Fair Value Instruments (Tables)

Fair Value Instruments (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2018 and December 31, 2017, respectively: Balance at June 30, 2018 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 5,525,432 $ — $ — $ 5,525,432 Investments available-for-sale at fair value U.S. government obligations $ 11,989,585 $ — $ — $ 11,989,585 Corporate debt securities $ — $ 22,966,351 $ — $ 22,966,351 Total $ 17,515,017 $ 22,966,351 $ — $ 40,481,368 Balance at December 31, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 8,521,054 $ — $ — $ 8,521,054 Total $ 8,521,054 $ — $ — $ 8,521,054

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	6 Months Ended
	Jun. 30, 2018
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities at June 30, 2018: June 30, 2018 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 11,997,649 $ — $ (8,064 ) $ 11,989,585 Corporate debt securities 22,969,626 — (3,275 ) 22,966,351 Total available-for-sale securities $ 34,967,275 $ — $ (11,339 ) $ 34,955,936
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities at June 30, 2018 are shown below. Under 1 Year 1 to 2 Years Total U.S. Treasury securities $ 11,989,585 $ — $ 11,989,585 Corporate debt securities 22,966,351 — 22,966,351 Total available-for-sale securities $ 34,955,936 $ — $ 34,955,936
Summary of Debt Securities with Unrealized Losses	The following table shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of June 30, 2018: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses U.S. Treasury securities $ 11,989,585 $ (8,064 ) $ — $ — $ 11,989,585 $ (8,064 ) Corporate debt securities 2,391,305 (3,275 ) — — 2,391,305 (3,275 ) Total available-for-sale securities with unrealized losses $ 14,380,890 $ (11,339 ) $ — $ — $ 14,380,890 $ (11,339 )

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net, consists of the following as of the dates indicated: June 30, December 31, 2018 2017 Furniture & fixtures $ 686,349 $ 582,007 Leasehold improvements 1,895,216 1,863,698 Equipment used in manufacturing 2,147,331 1,963,558 Equipment used in research & development 1,456,954 1,328,556 Equipment used in the field 130,552 130,552 Software 373,683 373,683 Construction in progress 158,211 255,641 6,848,296 6,497,695 Less: accumulated depreciation and amortization (3,959,301 ) (3,192,805 ) $ 2,888,995 $ 3,304,890

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following as of the dates indicated: June 30, December 31, 2018 2017 Accrued employee bonuses $ 1,365,489 $ 3,049,109 Payroll and employee benefit accruals 623,713 369,275 Accrued professional fees 112,320 101,150 Accrued interest 107,116 45,544 Other accrued liabilities 219,138 181,708 $ 2,427,776 $ 3,746,786

Revenue from Contracts with C32

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2018
Revenue From Contract With Customer [Abstract]
Product and Product-Related Service Revenue from Sale of Instruments and Consumables	Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and six months ended June 30, 2018 and 2017 as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Product revenue: Instruments $ 273,509 $ 148,479 $ 284,867 $ 171,058 Consumables 593,100 258,698 845,112 777,263 Total product revenue 866,609 407,177 1,129,979 948,321 Product-related services revenue: Custom RUO assay development 176,697 304,661 303,724 345,948 Sample processing 980,006 746,507 2,323,155 1,535,245 Total product-related services revenue 1,156,703 1,051,168 2,626,879 1,881,193 Total product and product-related services revenue $ 2,023,312 $ 1,458,345 $ 3,756,858 $ 2,829,514
Schedule of Collaborative Development Services	Collaborative Development Services Revenue Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Collaborative development services $ 2,887,454 $ 302,411 $ 5,312,560 $ 302,411
Schedule of Changes in Contract Liability	Changes in the Company’s contract liability were as follows as of the date indicated: Product Revenue Custom RUO Assay Design Sample Processing Collaborative Development Services Total Contract Liability Balance at January 1, 2018 $ 39,426 $ 197,606 $ 354,911 $ 245,942 $ 837,885 Deferral of revenue 90,353 231,500 72,540 70,918 465,311 Recognition of deferred revenue (91,797 ) (301,224 ) (262,723 ) (198,735 ) (854,479 ) Balance at June 30, 2018 $ 37,982 $ 127,882 $ 164,728 $ 118,125 $ 448,717

Other Agreements (Tables)

Other Agreements (Tables)	6 Months Ended
	Jun. 30, 2018
Other Agreements [Abstract]
Schedule of Remaining Minimum Principal Payments Due	The minimum remaining payments due to NuvoGen at June 30, 2018, including $194,646 of additional revenue-based payments payable as of June 30, 2018, are as follows for each fiscal year, although actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue exceeds $400,000: 2018 $ 394,646 2019 400,000 2020 400,000 2021 400,000 2022 400,000 2023 and beyond 5,469,004 Total NuvoGen obligation payments 7,463,650 Plus interest accretion 112,606 Total NuvoGen obligation, net $ 7,576,256

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides the numerator and denominator used in computing basic and diluted net loss per share for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator: Net loss $ (4,102,729 ) $ (5,840,902 ) $ (9,482,676 ) $ (11,657,176 ) Denominator: Weighted-average shares outstanding-basic and diluted 28,375,379 9,769,322 26,549,895 8,875,177 Net loss per share, basic and diluted $ (0.14 ) $ (0.60 ) $ (0.36 ) $ (1.31 )
Outstanding Securities Excluded from Computation of Diluted Net Loss per Share	The following outstanding securities were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2018 2017 Options to purchase common stock 1,693,575 1,436,978 Common stock warrants 237,846 219,723 Restricted stock units 26,666 208,999 QNAH convertible note 766,381 —

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2018
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	The following table shows the common stock warrants outstanding as of June 30, 2018: Shares of Common Exercise Price/Share Expiration Date 28,713 23.51 2024 144,772 14.00 2022 931 6.45 2019 45,307 2.76 2026 18,123 7.73 2028

Stockholders Deficit (Tables)

Stockholders Deficit (Tables)	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Summary of Stock Option Plans Activity	A summary of the Company’s stock option activity for the six months ended June 30, 2018 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2017 1,517,771 $ 2.97 7.5 $ 67,242 Granted 272,500 3.38 Exercised (33,651 ) 2.07 $ 51,816 Forfeited (23,190 ) 3.60 Expired/Cancelled (39,855 ) 6.83 Balance at June 30, 2018 1,693,575 $ 2.95 7.4 $ 1,262,339 Exercisable at June 30, 2018 1,163,017 $ 2.89 6.6 $ 1,061,522
Summary of Restricted Stock Unit (“RSU”) Plans Activity	A summary of restricted stock unit (“RSU”) activity for the six months ended June 30, 2018 is as follows: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2017 26,666 $ 2.78 Granted 269,551 3.82 Vested (269,551 ) 3.76 Balance at June 30, 2018 26,666 $ 3.34
Summary of Stock-Based Compensation	Stock-based compensation expense recorded in the accompanying interim unaudited condensed statements of operations for the three and six months ended June 30, 2018 and 2017 was as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Selling, general and administrative $ 173,666 $ 294,591 $ 1,275,658 $ 574,174 Research and development 49,189 93,103 80,098 181,464 Cost of revenue 19,065 30,243 29,622 58,945 $ 241,920 $ 417,937 $ 1,385,378 $ 814,583

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Minimum Real Estate Lease Payments Before Common Area Maintenance Charges	The Company’s remaining minimum real estate lease payments before common area maintenance charges for each fiscal year as of June 30, 2018 are as follows: 2018 $ 256,166 2019 514,977 2020 517,457 2021 43,139 $ 1,331,739
Summary of Product Warranty Reserve	The following is a summary of the Company’s general product warranty reserve for the periods indicated: Six Months Ended June 30, 2018 2017 Beginning balance $ 37,156 $ 50,426 Cost of warranty claims (2,358 ) (4,296 ) Increase (decrease) in warranty reserve 24,857 (14,817 ) Ending balance $ 59,655 $ 31,313

Description of Business - Addit

Description of Business - Additional Information (Details) - Segment	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Significant Accounting Policies [Line Items]
Number of operating segments			1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	74.00%	34.00%	76.00%	27.00%
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States | QIAGEN Manchester Limited
Significant Accounting Policies [Line Items]
Sales revenue percentage	80.00%	46.00%	77.00%	33.00%

Basis of Presentation and Sum39

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Oct. 31, 2017USD ($)	Jun. 30, 2018USD ($)Customer	Jun. 30, 2017Customer	Jun. 30, 2018USD ($)Customer	Jun. 30, 2017Customer	Dec. 31, 2017Customer
Significant Accounting Policies [Line Items]
Prior period reclassification adjustment				$ 0
Accounting Standards Update 2016-02 | Maximum | Office and Equipment Leases
Significant Accounting Policies [Line Items]
Gross-up amount of leases effect in balance sheets				$ 2,000,000
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer		3	3	3	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage		59.00%	16.00%	59.00%	16.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage		11.00%	15.00%	10.00%	12.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage		5.00%	13.00%	5.00%	9.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer				2		2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage				59.00%		66.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage				15.00%		11.00%
NuvoGen Asset Purchase Agreement
Significant Accounting Policies [Line Items]
Percentage of revenue for remaining payment due under obligation				6.00%
QIAGEN North American Holdings, Inc.
Significant Accounting Policies [Line Items]
Convertible debt, fair value		$ 3,400,000		$ 3,400,000
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Significant Accounting Policies [Line Items]
Gross proceeds from issuance of subordinated notes	$ 3,000,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 882,396	$ 984,328
Work in process	81,237	66,314
Finished goods	101,245	192,021
Total gross inventory	1,064,878	1,242,663
Less inventory allowance	(62,329)	(62,142)
Inventory, net	$ 1,002,549	$ 1,180,521

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Inventory Disclosure [Abstract]
Reserve for shrinkage and excess inventory			$ 62,329		$ 62,142
Net change in inventory valuation reserves	$ (1,614)	$ (66,250)	187	$ (62,427)
Provision for excess inventory	$ 12,253	$ 51,599	$ 23,533	$ 244,026

Fair Value Instruments - Financ

Fair Value Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Asset included in:
Financial Assets	$ 40,481,368	$ 8,521,054
Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	5,525,432	8,521,054
Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets	11,989,585
Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	22,966,351
Level 1
Asset included in:
Financial Assets	17,515,017	8,521,054
Level 1 | Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	5,525,432	$ 8,521,054
Level 1 | Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets	11,989,585
Level 2
Asset included in:
Financial Assets	22,966,351
Level 2 | Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	$ 22,966,351

Fair Value Instruments - Additi

Fair Value Instruments - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0	$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 34,967,275
Gross Unrealized Losses	(11,339)
Fair Value (Net Carrying Amount)	34,955,936	$ 0
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	11,997,649
Gross Unrealized Losses	(8,064)
Fair Value (Net Carrying Amount)	11,989,585
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	22,969,626
Gross Unrealized Losses	(3,275)
Fair Value (Net Carrying Amount)	$ 22,966,351

Available-for-Sale Securities45

Available-for-Sale Securities - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Investments Debt And Equity Securities [Abstract]
Available for sale securities	$ 34,955,936		$ 34,955,936		$ 0
Unrealized gain on short and long-term investments	$ (188)	$ 736	(11,339)	$ 1,090
Available-For-Sale Securities
Schedule Of Available For Sale Securities [Line Items]
Other-than-temporary impairment			$ 0		$ 0

Available-for-Sale Securities46

Available-for-Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 34,955,936
Fair Value (Net Carrying Amount)	34,955,936	$ 0
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	11,989,585
Fair Value (Net Carrying Amount)	11,989,585
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	22,966,351
Fair Value (Net Carrying Amount)	$ 22,966,351

Available-for-Sale Securities47

Available-for-Sale Securities - Summary of Debt Securities with Unrealized Losses (Details)	Jun. 30, 2018USD ($)
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	$ 14,380,890
Under 1 Year, Gross Unrealized Losses	(11,339)
Total, Fair Value	14,380,890
Total, Gross Unrealized Losses	(11,339)
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	11,989,585
Under 1 Year, Gross Unrealized Losses	(8,064)
Total, Fair Value	11,989,585
Total, Gross Unrealized Losses	(8,064)
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	2,391,305
Under 1 Year, Gross Unrealized Losses	(3,275)
Total, Fair Value	2,391,305
Total, Gross Unrealized Losses	$ (3,275)

Summary Of Property and Equipme

Summary Of Property and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Furniture & fixtures	$ 686,349	$ 582,007
Leasehold improvements	1,895,216	1,863,698
Equipment used in manufacturing	2,147,331	1,963,558
Equipment used in research & development	1,456,954	1,328,556
Equipment used in the field	130,552	130,552
Software	373,683	373,683
Construction in progress	158,211	255,641
Total property and equipment, gross	6,848,296	6,497,695
Less: accumulated depreciation and amortization	(3,959,301)	(3,192,805)
Property and equipment, net	$ 2,888,995	$ 3,304,890

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 422,140	$ 291,421	$ 778,344	$ 587,466

Summary of Accrued Liabilities

Summary of Accrued Liabilities (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Accrued employee bonuses	$ 1,365,489	$ 3,049,109
Payroll and employee benefit accruals	623,713	369,275
Accrued professional fees	112,320	101,150
Accrued interest	107,116	45,544
Other accrued liabilities	219,138	181,708
Total accrued liabilities	$ 2,427,776	$ 3,746,786

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details) - USD ($)	Mar. 26, 2018	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Debt Instrument [Line Items]
Accretion of discount on NuvoGen obligation					$ (6,006)	$ 99,377
Repayment of outstanding principal and interest					4,276,988
Loss on extinguishment of Growth Term Loan					105,064
Warrants to purchase common stock, shares		18,123
Warrants exercise price		$ 7.73
Revolving loan cost			$ 75,184		75,184
MidCap Credit Facility
Debt Instrument [Line Items]
Accretion of discount on NuvoGen obligation			41,155		$ 43,856
Credit facility aggregate principal amount	$ 20,000,000
Line of credit facility interest rate at the end of the period	9.34%
Line of credit facility, expiration period	36 months
Line of credit facility first anniversary early termination fee percentage	3.00%
Line of credit facility second anniversary early termination fee percentage	2.00%
Line of credit facility third anniversary early termination fee percentage	1.00%
Origination fee	$ 100,000
Line of credit facility termination fee	4.50%
Amount required to deposit in escrow account	$ 3,300,000
Credit facility, covenant terms					Commencing with the calendar quarter ending on the later of (a) June 30, 2019 and (b) the last day of the calendar quarter in which MidCap Tranche 2 is funded, the Company must also comply with a financial covenant relating to trailing twelve-month minimum Net Revenue requirements (as defined in the MidCap Credit Facility), tested on a quarterly basis
Credit Facility increase in interest on obligation percentage	3.00%
Percentage of weighted average closing price	150.00%
Fair value of warrants	$ 74,000
Debt discount			729,269		$ 729,269
MidCap Credit Facility | MidCap Tranche 1
Debt Instrument [Line Items]
Credit facility aggregate principal amount	$ 7,000,000
Line of credit facility interest rate	7.25%
Credit facility, basis spread on variable rate	1.25%
Credit facility, basis spread on variable rate description	one-month LIBOR
Warrants to purchase of common stock expiration year	10 years
Warrants to purchase common stock, shares	18,123
Warrants exercise price	$ 7.73
MidCap Credit Facility | MidCap Tranche 2
Debt Instrument [Line Items]
Credit facility aggregate principal amount	$ 13,000,000
Line of credit facility interest rate	7.25%
Credit facility, basis spread on variable rate	1.25%
Credit facility, basis spread on variable rate description	one-month LIBOR
Warrants to purchase of common stock expiration year	10 years
Percentage of warrants to purchase common stock	2.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Amortization of deferred financing costs			4,013		4,236
Credit facility aggregate principal amount	$ 2,000,000
Line of credit facility interest rate	4.25%
Credit facility, basis spread on variable rate	1.25%
Credit facility, basis spread on variable rate description	one-month LIBOR
Line of credit facility first anniversary early termination fee percentage	3.00%
Line of credit facility second anniversary early termination fee percentage	2.00%
Line of credit facility third anniversary early termination fee percentage	1.00%
Credit facility outstanding amount			0		0
Credit facility origination fee percentage	0.50%
Credit facility, unused line fee percentage	0.50%
Credit facility collateral management fee percentage	0.50%
Credit facility minimum drawn balance percentage	20.00%
Revolving loan cost			75,184		75,184
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Credit facility additional borrowing capacity	$ 8,000,000
Growth Term Loan
Debt Instrument [Line Items]
Accretion of discount on NuvoGen obligation					0		$ 58,538
Amortization of deferred financing costs			0	$ 4,995	2,982	10,588
Repayment of outstanding principal and interest		$ 4,300,000
Loss on extinguishment of Growth Term Loan			0		105,064
Unamortized discounts			67,272		67,272
Growth Term Loan | Oxford Finance, LLC and Silicon Valley Bank
Debt Instrument [Line Items]
Accretion of discount on NuvoGen obligation			$ 0	$ 103,741	$ 59,969	$ 220,731

Revenue from Contracts with C52

Revenue from Contracts with Customers - Product and Product-Related Service Revenue from Sale of Instruments and Consumables (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 2,023,312	$ 1,458,345	$ 3,756,858	$ 2,829,514
Product-related services revenue	2,887,454	302,411	5,312,560	302,411
HTG EdgeSeq
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	866,609	407,177	1,129,979	948,321
Product-related services revenue	1,156,703	1,051,168	2,626,879	1,881,193
HTG EdgeSeq | Instrument
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	273,509	148,479	284,867	171,058
HTG EdgeSeq | Consumables
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	593,100	258,698	845,112	777,263
HTG EdgeSeq | Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Product-related services revenue	176,697	304,661	303,724	345,948
HTG EdgeSeq | Sample processing
Disaggregation Of Revenue [Line Items]
Product-related services revenue	$ 980,006	$ 746,507	$ 2,323,155	$ 1,535,245

Revenue from Contracts with C53

Revenue from Contracts with Customers - Additional Information (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue				1 year
Agreements for product and product-related services revenue, description				The Company’s agreements for product and product-related services revenue have an expected duration of one year or less
Product and product-related services revenue	$ 2,023,312	$ 1,458,345		$ 3,756,858	$ 2,829,514
Contract liabilities	448,717			448,717		$ 837,885
Collaborative development services	2,887,454	302,411		5,312,560	302,411
Cumulative catch up adjustment	0			30,055
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Contract liabilities	118,125			$ 118,125		245,942
Bristol Myers Squibb
Disaggregation Of Revenue [Line Items]
Agreement expiration date				May 11, 2019
Number of days material breach remains uncured				60 days
Agreement termination notice period				90 days
Product and product-related services revenue	70,919		$ 31,250	$ 132,224	62,500
Contract liabilities	90,382			90,382		$ 160,106
Partially unsatisfied performance obligation aggregate amount	50,000			50,000
Merck KGaA Agreement | Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Collaborative development services	$ 0	$ 25,000		$ 0	$ 25,000
Minimum
Disaggregation Of Revenue [Line Items]
Customer payment term				30 days
Maximum
Disaggregation Of Revenue [Line Items]
Customer payment term				90 days

Revenue from Contract with Cust

Revenue from Contract with Customer - Schedule of Collaborative Development Services (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue From Contract With Customer [Abstract]
Collaborative development services	$ 2,887,454	$ 302,411	$ 5,312,560	$ 302,411

Revenue from Contract with Cu55

Revenue from Contract with Customer - Schedule of Changes in Contract Liability (Details)	6 Months Ended
	Jun. 30, 2018USD ($)
Disaggregation Of Revenue [Line Items]
Beginning Balance	$ 837,885
Deferral of revenue	465,311
Recognition of deferred revenue	(854,479)
Ending Balance	448,717
Product Revenue
Disaggregation Of Revenue [Line Items]
Beginning Balance	39,426
Deferral of revenue	90,353
Recognition of deferred revenue	(91,797)
Ending Balance	37,982
Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Beginning Balance	197,606
Deferral of revenue	231,500
Recognition of deferred revenue	(301,224)
Ending Balance	127,882
Sample processing
Disaggregation Of Revenue [Line Items]
Beginning Balance	354,911
Deferral of revenue	72,540
Recognition of deferred revenue	(262,723)
Ending Balance	164,728
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Beginning Balance	245,942
Deferral of revenue	70,918
Recognition of deferred revenue	(198,735)
Ending Balance	$ 118,125

Other Agreements - Additional I

Other Agreements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Other Agreements [Line Items]
Research and development	$ 2,758,984	$ 1,618,889	$ 5,348,270	$ 2,885,952
Illumina, Inc. Agreement
Other Agreements [Line Items]
Research and development		$ 50,000		$ 50,000
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018	400,000		$ 400,000
Percentage on annual revenues for cash consideration to be paid			6.00%
Accrued revenue-based payments					$ 0
Asset purchase agreement fixed quarterly payments	100,000		$ 100,000
Additional revenue based payments payable	$ 194,646		$ 194,646		$ 85,574

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Minimum Principal Payments Due (Details) - NuvoGen Asset Purchase Agreement	Jun. 30, 2018USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2,018	$ 394,646
2,019	400,000
2,020	400,000
2,021	400,000
2,022	400,000
2023 and beyond	5,469,004
Total NuvoGen obligation payments	7,463,650
Plus interest accretion	112,606
Total NuvoGen obligation, net	$ 7,576,256

Net Loss per Share - Numerator

Net Loss per Share - Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator:
Net loss	$ (4,102,729)	$ (5,840,902)	$ (9,482,676)	$ (11,657,176)
Denominator:
Weighted-average shares outstanding-basic and diluted	28,375,379	9,769,322	26,549,895	8,875,177
Net loss per share, basic and diluted	$ (0.14)	$ (0.60)	$ (0.36)	$ (1.31)

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Securities Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	1,693,575	1,436,978
Restricted Stock Units R S U
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	26,666	208,999
Warrant | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	237,846	219,723
QNAH convertible note
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	766,381

Warrants - Additional Informati

Warrants - Additional Information (Details) - $ / shares	6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Warrants And Rights Note Disclosure [Abstract]
Warrants issued to acquire shares		18,123
Warrants exercise price		$ 7.73
Warrants expiration date	Mar. 31, 2018
Warrants expiration description	tenth anniversary

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Class Of Warrant Or Right [Line Items]
Exercise Price/Share		$ 7.73
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	144,772
Exercise Price/Share	$ 14
Expiration Date	2,022
Common Stock Warrants one
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	931
Exercise Price/Share	$ 6.45
Expiration Date	2,019
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	45,307
Exercise Price/Share	$ 2.76
Expiration Date	2,026
Common Stock Tranche one
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	18,123
Exercise Price/Share	$ 7.73
Expiration Date	2,028
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Shares of Common Stock Underlying Warrants	28,713
Exercise Price/Share	$ 23.51
Expiration Date	2,024

Stockholders Deficit - Addition

Stockholders Deficit - Additional Information (Details) - USD ($)	Jan. 31, 2018	Jan. 29, 2018	Jun. 30, 2017	Apr. 30, 2017	Jun. 30, 2018	Jan. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Class Of Stock [Line Items]
Issuance of common stock from the ATM Offering, Shares								5,733,314
Gross proceeds from issuance of common stock								$ 21,100,000
Sales commission								600,000
Other offering expenses paid								200,000
Net proceeds from issuance of common stock from the ATM Offering								$ 20,200,000
Accelerated vesting of stock options					46,613
Options extended exercise period					1 year
Incremental stock-based compensation expense							$ 79,400			$ 79,400
Stock-based compensation							241,920		$ 417,937	1,385,378	$ 814,583
Selling, General and Administrative
Class Of Stock [Line Items]
Stock-based compensation							173,666		$ 294,591	1,275,658	$ 574,174
Restricted Stock Units R S U
Class Of Stock [Line Items]
Unrecognized compensation expense					$ 70,313		70,313			$ 70,313
Compensation expense period expected to be recognized										2 years 6 months 21 days
Issuance of shares granted										269,551
Restricted stock grant date fair value										$ 3.82
Restricted Stock Units R S U | Executive Officers
Class Of Stock [Line Items]
Issuance of shares granted		259,551
Restricted stock grant date fair value		$ 3.84
Restricted Stock Units R S U | Selling, General and Administrative | Executive Officers
Class Of Stock [Line Items]
Stock-based compensation							1,000,000			$ 1,000,000
Two Thousand Fourteen Equity Incentive Plan | Employee Stock Option
Class Of Stock [Line Items]
Unrecognized compensation expense					$ 937,490		$ 937,490			$ 937,490
Compensation expense period expected to be recognized										2 years 11 months 23 days
Underwritten Public Offering
Class Of Stock [Line Items]
Common stock price per share	$ 2.90					$ 2.90
Issuance of common stock from the ATM Offering, Shares						13,915,000
Net proceeds from initial public offering after underwriters' discounts, commissions and offering expenses						$ 37,700,000
Over-Allotment Option
Class Of Stock [Line Items]
Issuance of common stock from the ATM Offering, Shares						1,815,000
Common Stock
Class Of Stock [Line Items]
Issuance of common stock from the ATM Offering, Shares								300,000
Gross proceeds from issuance of common stock								$ 600,000
Sales Agreement
Class Of Stock [Line Items]
Common stock price per share				$ 0.001
Common stock aggregate offering price	$ 23,000,000		$ 40,000,000	$ 20,000,000

Stockholders Deficit - Summary

Stockholders Deficit - Summary of Stock Option Plans Activity (Details) - Employee Stock Option - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,517,771
Number of Shares, Granted	272,500
Number of Shares, Exercised	(33,651)
Number of Shares, Forfeited	(23,190)
Number of Shares, Expired/Cancelled	(39,855)
Number of Shares, Ending Balance	1,693,575	1,517,771
Number of Shares, Exercisable	1,163,017
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 2.97
Weighted-Average Exercise Price Per Share, Granted	3.38
Weighted-Average Exercise Price Per Share, Exercised	2.07
Weighted-Average Exercise Price Per Share, Forfeited	3.60
Weighted-Average Exercise Price Per Share, Expired/Cancelled	6.83
Weighted-Average Exercise Price Per Share, Ending Balance	2.95	$ 2.97
Weighted-Average Exercise Price Per Share, Exercisable	$ 2.89
Weighted-Average Remaining Contractual Life, Outstanding	7 years 4 months 24 days	7 years 6 months
Weighted-Average Remaining Contractual Life, Exercisable	6 years 7 months 6 days
Aggregate Intrinsic Value, Balance	$ 1,262,339	$ 67,242
Aggregate Intrinsic Value, Exercised	51,816
Aggregate Intrinsic Value, Exercisable	$ 1,061,522

Stockholders Deficit - Summar64

Stockholders Deficit - Summary of Restricted Stock Unit ('RSU') Plans Activity (Details) - Restricted Stock Units R S U	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Restricted Stock Units (RSU)
Beginning Balance | shares	26,666
Granted | shares	269,551
Vested | shares	(269,551)
Ending Balance | shares	26,666
Weighted Average Grant Date Fair Value Per Share
Beginning Balance | $ / shares	$ 2.78
Granted | $ / shares	3.82
Vested | $ / shares	3.76
Ending Balance | $ / shares	$ 3.34

Stockholders Deficit - Summar65

Stockholders Deficit - Summary of Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 241,920	$ 417,937	$ 1,385,378	$ 814,583
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	173,666	294,591	1,275,658	574,174
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	49,189	93,103	80,098	181,464
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 19,065	$ 30,243	$ 29,622	$ 58,945

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2018USD ($)
Commitments And Contingencies [Line Items]
Lease expiration term		The Company leases office and laboratory space in Tucson, Arizona under two non-cancelable operating leases.
Computer Equipment
Commitments And Contingencies [Line Items]
Capital lease commitments	$ 88,700	$ 88,700
Computer Equipment | Minimum
Commitments And Contingencies [Line Items]
Capital lease commitment period		36 months
Computer Equipment | Maximum
Commitments And Contingencies [Line Items]
Capital lease commitment period		48 months
Non-Executive Officer Employees
Commitments And Contingencies [Line Items]
Compensation expenses	$ 244,588	$ 472,813

Commitments and Contingencies67

Commitments and Contingencies - Minimum Real Estate Lease Payments Before Common Area Maintenance Charges (Details)	Jun. 30, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,018	$ 256,166
2,019	514,977
2,020	517,457
2,021	43,139
Total minimum lease payments	$ 1,331,739

Commitments and Contingencies68

Commitments and Contingencies - Schedule Of Product Warranty Reserve (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 37,156	$ 50,426
Cost of warranty claims	(2,358)	(4,296)
Increase (decrease) in warranty reserve	24,857	(14,817)
Ending balance	$ 59,655	$ 31,313

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income tax examination, likelihood of unfavorable settlement			greater than 50 percent
Uncertain tax positions	$ 0		$ 0	$ 0
Accrued interest or penalties	0		0	0
Recognized interest or penalties	$ 0	$ 0
Income taxes paid other than state minimum taxes			$ 0	$ 0
U.S. federal corporate tax rate			21.00%	35.00%
Tax cuts and jobs act of 2017, change in tax rate, decrease in deferred tax assets			$ 16,232,211
Tax cuts and jobs act of 2017, change in tax rate, net adjustment in deferred tax expense			$ 0
Percentage of taxable income in utilization of net operating losses			80.00%
Net operating loss carryforwards expiration period			20 years

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Oct. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Related Party Transaction [Line Items]
Collaborative development services		$ 2,887,454	$ 302,411	$ 5,312,560	$ 302,411
Accounts receivable		3,481,994		3,481,994		$ 6,356,268
Research and development		2,758,984	1,618,889	5,348,270	2,885,952
Revenues		4,910,766	1,760,756	9,069,418	3,131,925
SOW One
Related Party Transaction [Line Items]
Collaborative development services		1,078,418	277,400	2,397,136	277,400
Profit sharing payments included in collaborative development services revenue		0		99,394
Accounts receivable		429,019		429,019		2,429,152
Research and development		669,994	222,200	1,716,115	222,200
SOW Two
Related Party Transaction [Line Items]
Collaborative development services		869,827		1,480,818
Profit sharing payments included in collaborative development services revenue		0		386,369
Accounts receivable		729,448		729,448		1,796,157
Research and development		420,876		764,142
Costs			0		0
Revenues			0		0
SOW Three
Related Party Transaction [Line Items]
Collaborative development services		939,209		1,434,606
Profit sharing payments included in collaborative development services revenue		0		0
Accounts receivable		879,526		879,526		0
Research and development		627,709		$ 854,564
Costs			0		0
Revenues			0		0
QIAGEN Manchester Limited
Related Party Transaction [Line Items]
Agreement commencement period				2016-11
QIAGEN Manchester Limited | Maximum
Related Party Transaction [Line Items]
Term of Agreement				1 year
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Related Party Transaction [Line Items]
Cash proceeds from issuance of subordinated notes	$ 3,000,000
Unamortized deferred financing costs		32,513		$ 32,513		$ 39,240
QIAGEN North American Holdings, Inc. | Convertible Promissory Note | Interest Expense
Related Party Transaction [Line Items]
Amortization of deferred financing costs		3,364	0	6,727	0
Interest accrued		$ 22,438	$ 0	$ 44,630	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	Aug. 08, 2018	Jul. 11, 2018	Mar. 26, 2018
Subsequent Event | SOW Two | QIAGEN Manchester Limited
Subsequent Event [Line Items]
Due from related parties	$ 0.5
MidCap Credit Facility
Subsequent Event [Line Items]
Amount required to deposit in escrow account			$ 3.3
Minimum amount in deposit account subject to control agreement			$ 20
MidCap Credit Facility | Subsequent Event
Subsequent Event [Line Items]
Escrow deposit		$ 3.3